Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Obsessive-Compulsive Disorder (OCD) Therapeutics market. The report identifies the key trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Obsessive-Compulsive Disorder (OCD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Obsessive-Compulsive Disorder (OCD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Obsessive-Compulsive Disorder (OCD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Obsessive-Compulsive Disorder (OCD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Obsessive-Compulsive Disorder (OCD) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Obsessive-Compulsive Disorder (OCD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Obsessive-Compulsive Disorder (OCD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Obsessive-Compulsive Disorder (OCD) Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Transcept Pharmaceuticals, Inc.

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 OCD Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 6
2.3 Etiology and Pathophysiology 7
2.4 Signs and Symptoms 7
2.5 Treatment 7
2.6 Referral Pathway 8
2.7 GlobalData Pipeline Report Guidance 9
3 OCD Therapeutics - Market Characterization 10
3.1 OCD Therapeutics Market Size (2005–2010) – Global 10
3.2 OCD Therapeutics Market Forecast (2010–2017) – Global 11
3.3 OCD Therapeutics Market Size (2005–2010) – The US 12
3.4 OCD Therapeutics Market Forecast (2010–2017) – The US 13
3.5 OCD Therapeutics Market Size (2005–2010) – France 14
3.6 OCD Therapeutics Market Forecast (2010–2017) – France 15
3.7 OCD Therapeutics Market Size (2005–2010) – Germany 16
3.8 OCD Therapeutics Market Forecast (2010–2017) – Germany 17
3.9 OCD Therapeutics Market Size (2005–2010) – Italy 18
3.10 OCD Therapeutics Market Forecast (2010–2017) – Italy 19
3.11 OCD Therapeutics Market Size (2005–2010) – Spain 20
3.12 OCD Therapeutics Market Forecast (2010–2017) – Spain 21
3.13 OCD Therapeutics Market Size (2005–2010) – The UK 22
3.14 OCD Therapeutics Market Forecast (2010–2017) – The UK 23
3.15 OCD Therapeutics Market Size (2005–2010) – Japan 24
3.16 OCD Therapeutics Market Forecast (2010–2017) – Japan 25
3.17 Drivers and Barriers for the OCD Therapeutics Market 26
3.17.1 Drivers for the OCD Therapeutics Market 26
3.17.2 Barriers for the OCD Therapeutics Market 26
3.18 Opportunity and Unmet Need Analysis 27
3.19 Key Takeaway 27
4 OCD Therapeutics - Competitive Assessment 28
4.1 Overview 28
4.2 Strategic Competitor Assessment 28
4.3 Product Profiles for the Major Marketed Products in the OCD Therapeutics Market 29
4.3.1 Paxil (paroxetine) 29
4.3.2 Zoloft (sertraline hydrochloride) 30
4.3.3 Luvox CR (fluvoxamine) 31
4.3.4 Prozac (fluoxetine hydrochloride) 32
4.3.5 Anafranil (clomipramine hydrochloride) 33
4.4 Key Takeaway 33
5 OCD Therapeutics - Pipeline Assessment 34
5.1 Overview 34
5.2 Strategic Pipeline Assessment 34
5.3 OCD Therapeutics Pipeline – Pipeline by Phases of Development 34
5.3.1 OCD Therapeutics – Phase III Pipeline 34
5.3.2 OCD Therapeutics – Phase II Pipeline 35
5.3.3 OCD Market – Discovery and Pre-clinical Pipeline 35
5.3.4 Technology Trends Analytic Framework 36
5.4 OCD Therapeutics Market – Clinical Pipeline by Mechanism of Action 37
5.5 OCD Therapeutics – Promising Drugs Under Clinical Development 37
5.6 Molecule Profile for Promising Drugs Under Clinical Development 38
5.6.1 Gamunex-C 38
5.7 Key Takeaway 38
6 OCD Therapeutics - Clinical Trials Mapping 39
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 39
6.2 Clinical Trials by Phase 40
6.3 Clinical Trials by Trial Status 41
6.4 Prominent Sponsors 42
6.5 Top Companies Participating in OCD Therapeutics Clinical Trials 44
7 Strategic Assessment 45
7.1 Key Events Impacting the Future Market 45
7.2 OCD Therapeutics - Implications for Future Market Competition 46
8 OCD Therapeutics - Future Players 47
8.1 Introduction 47
8.2 Company Profiles 48
8.2.1 Transcept Pharmaceuticals, Inc. 48
9 OCD Therapeutics - Licensing and Partnership Deals 49
10 OCD Therapeutics - Appendix 50
10.1 Market Definitions 50
10.2 Abbreviations 50
10.2.1 Methodology 50
10.2.2 Coverage 51
10.2.3 Secondary Research 51
10.2.4 Forecasting 51
10.2.5 Primary Research 54
10.2.6 Expert Panel Validation 54
10.3 Contact Us 54
10.4 Disclaimer 54
10.5 Bibliography 55"

1.1 List of Tables
Table 1: Common Obsessions in OCD 6
Table 2: OCD Therapeutics Market, Global, Revenue ($m), 2005–2010 10
Table 3: OCD Therapeutics Market, Global, Forecast ($m), 2010–2017 11
Table 4: OCD Therapeutics Market, The US, Revenue ($m), 2005–2010 12
Table 5: OCD Therapeutics Market, The US, Forecasts ($m), 2010–2017 13
Table 6: OCD Therapeutics Market, France, Revenue ($m), 2005–2010 14
Table 7: OCD Therapeutics Market, France, Forecasts ($m), 2010–2017 15
Table 8: OCD Therapeutics Market, Germany, Revenue ($m), 2005–2010 16
Table 9: OCD Therapeutics Market, Germany, Forecasts ($m), 2010–2017 17
Table 10: OCD Therapeutics Market, Italy, Revenue ($m), 2005–2010 18
Table 11: OCD Therapeutics Market, Italy, Forecasts ($m), 2010–2017 19
Table 12: OCD Therapeutics Market, Spain, Revenue ($m), 2005–2010 20
Table 13: OCD Therapeutics Market, Spain, Forecasts ($m), 2010–2017 21
Table 14: OCD Therapeutics Market, The UK, Revenue ($m), 2005–2010 22
Table 15: OCD Therapeutics Market, The UK, Forecasts ($m), 2010–2017 23
Table 16: OCD Therapeutics Market, Japan, Revenue ($m), 2005–2010 24
Table 17: OCD Therapeutics Market, Japan, Forecasts ($m), 2010–2017 25
Table 18: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 29
Table 19: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 32
Table 20: OCD Therapeutics, Phase III Pipeline, 2011 34
Table 21: OCD Therapeutics, Phase II Pipeline, 2011 35
Table 22: OCD Therapeutics, Discovery and Preclinical Pipeline, 2011 35
Table 23: OCD Therapeutics – Most Promising Drugs Under Clinical Development, 2011 37
Table 24: OCD Therapeutics, Clinical Trials by Country, 2011 39
Table 25: OCD Therapeutics – Clinical Trials by Phase, 2011 40
Table 26: OCD Therapeutics, Clinical Trials by Status (%), 2011 41
Table 27: OCD Therapeutics, Prominent Sponsors, 2011 43
Table 28: OCD Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 44
Table 29: Transcept Pharmaceuticals Inc., Product Pipeline, 2011 48
Table 30: OCD Therapeutics, Global, Deals, 2010-2011 49"

1.2 List of Figures
Figure 1: OCD Therapeutics Drug Dosage Pattern 7
Figure 2: Referral Pathway for Obsessive Compulsive Disorders 8
Figure 3: OCD Therapeutics Market, Global, Revenue ($m), 2005–2010 10
Figure 4: OCD Therapeutics Market, Global, Forecast ($m), 2010–2017 11
Figure 5: OCD Therapeutics Market, The US, Revenue ($m), 2005–2010 12
Figure 6: OCD Therapeutics Market, The US, Forecast ($m), 2010–2017 13
Figure 7: OCD Therapeutics Market, France, Revenue ($m), 2005–2010 14
Figure 8: OCD Therapeutics Market, France, Forecast ($m), 2010–2017 15
Figure 9: OCD Therapeutics Market, Germany, Revenue ($m), 2005–2010 16
Figure 10: OCD Therapeutics Market, Germany, Forecast ($m), 2010–2017 17
Figure 11: OCD Therapeutics Market, Italy, Revenue ($m), 2005–2010 18
Figure 12: OCD Therapeutics Market, Italy, Forecast ($m), 2010–2017 19
Figure 13: OCD Therapeutics Market, Spain, Revenue ($m), 2005–2010 20
Figure 14: OCD Therapeutics Market, Spain, Forecast ($m), 2010–2017 21
Figure 15: OCD Therapeutics Market, The UK, Revenue ($m), 2005–2010 22
Figure 16: OCD Therapeutics Market, The UK, Forecast ($m), 2010–2017 23
Figure 17: OCD Therapeutics Market, Japan, Revenue ($m), 2005–2010 24
Figure 18: OCD Therapeutics Market, Japan, Forecast ($m), 2010–2017 25
Figure 19: Opportunity and Unmet Need in the OCD Therapeutics Market, 2010 27
Figure 20: OCD Therapeutics, Strategic Competitor Assessment, 2010 28
Figure 21: OCD Therapeutics – Pipeline by Phase of Development, 2011 34
Figure 22: OCD Therapeutics, Technology Trends Analytics Framework, 2011 36
Figure 23: OCD Therapeutics, Technology Trends Analytics Framework, Description, 2011 36
Figure 24: OCD Therapeutics, Pipeline by Mechanism of Action (%), 2011 37
Figure 25: Gamunex-C Clinical Trial Details 38
Figure 26: OCD Therapeutics, Clinical Trials by Country, 2011 39
Figure 27: OCD Therapeutics, Clinical Trials by Phase (%), 2011 40
Figure 28: OCD Therapeutics, Clinical Trials by Status (%), 2011 41
Figure 29: OCD Therapeutics, Overall Sponsors (%), 2011 42
Figure 30: OCD Therapeutics, Prominent Sponsors (%), 2011 43
Figure 31: OCD Therapeutics, Top Companies Participating in Clinical Trials, 2011 44
Figure 32: OCD Therapeutics Market, Drivers and Restraints, 2011 45
Figure 33: Implications for Future Market Competition in the OCD Market, 2011 46
Figure 34: OCD Therapeutics Market, Pipeline by Company, 2011 47
Figure 35: GlobalData Market Forecasting Model 53